A greater understanding of the epidemiology, pathogen esis, and pathophysiology of pulmonary artery hypertension has led to significant advances, but the disease remains fatal
Treatment options are neither universally available nor always effective, underscoring the need for development of novel therapies and therapeutic strategies.
Clinical trial to date have provided evidence of efficacy, but were limited in evaluating the scope and duration of treatment effects